Related Experiment Video
Updated: Aug 6, 2026
Adenoviral Transduction of Naive CD4 T Cells to Study Treg Differentiation
Published on: August 13, 2013
DNA contamination within recombinant adeno-associated virus preparations correlates with decreased CD34+ cell
Christopher R Luthers1,2, Sung-Min Ha3, Annika Mittelhauser2
1Molecular Biology Interdepartmental Program, University of California, Los Angeles (UCLA), Los Angeles, CA, USA.
Abstract:
Recombinant adeno-associated viruses (rAAV) are promising for applications in many genome editing techniques through their effectiveness as carriers of DNA homologous donors into primary hematopoietic stem and progenitor cells (HSPCs), but they have many outstanding concerns. Specifically, their biomanufacturing and the variety of factors that influence the quality and consistency of rAAV preps are in question. During the process of rAAV packaging, a cell line is transfected with several DNA plasmids that collectively encode all the necessary information to allow for viral packaging. Ideally, this process results in the packaging of complete viral particles only containing rAAV genomes; however, this is not the case. Through this study, we were able to leverage single-stranded virus (SSV) sequencing, a next-generation sequencing-based method to quantify all DNA species present within rAAV preps. From this, it was determined that much of the DNA within some rAAV preps is not vector-genome derived, and there is wide variability in the contamination by DNA across various preps. Furthermore, we demonstrate that transducing CD34+ HSPCs with preps with higher contaminating DNA resulted in decreased clonogenic potential, altered transcriptomic profiles, and decreased genomic editing. Collectively, this study characterized the effects of DNA contamination within rAAV preps on CD34+ HSPC cellular potential.
Insights
DNA contamination in recombinant adeno-associated virus (rAAV) preparations significantly impacts hematopoietic stem and progenitor cells (HSPCs). This study quantifies DNA impurities in rAAV and reveals their detrimental effects on HSPC function and genome editing efficiency.
Area of Science:
- Molecular Biology
- Gene Therapy
- Cell Biology
Background:
- Recombinant adeno-associated viruses (rAAV) are critical vectors for gene therapy and genome editing, particularly for delivering DNA donors to hematopoietic stem and progenitor cells (HSPCs).
- Manufacturing of rAAV faces challenges related to the quality and consistency of viral preparations, with potential for non-vector DNA contamination.
- The impact of such DNA contaminants on the biological function of target cells remains incompletely understood.
Purpose of the Study:
- To quantify DNA species within rAAV preparations using single-stranded virus (SSV) sequencing.
- To investigate the relationship between the level of DNA contamination in rAAV and its effects on CD34+ HSPC potential.
- To assess the impact of DNA contamination on cellular function, transcriptomic profiles, and genome editing outcomes in HSPCs.
Main Methods:
- Utilized single-stranded virus (SSV) sequencing, a next-generation sequencing technique, to analyze DNA content in rAAV preparations.
- Quantified non-vector-derived DNA contaminants present in various rAAV batches.
- Transduced CD34+ HSPCs with rAAV preparations of varying DNA contamination levels and assessed cellular outcomes.
Main Results:
- SSV sequencing revealed significant variability and substantial amounts of non-vector-derived DNA in rAAV preparations.
- Transduction of CD34+ HSPCs with rAAV containing higher levels of DNA contamination led to reduced clonogenic potential.
- Increased DNA contamination in rAAV correlated with altered transcriptomic profiles and diminished genomic editing efficiency in HSPCs.
Conclusions:
- DNA contamination is a critical, variable issue in rAAV manufacturing that negatively affects HSPC function.
- The presence of non-vector DNA in rAAV preparations impairs cellular potential, including self-renewal and differentiation capacity.
- These findings highlight the need for stringent quality control in rAAV production to ensure therapeutic efficacy and safety in gene editing applications.
